Cargando…

1118. Population Pharmacokinetics of Contezolid Acefosamil and Contezolid – Rationale for a Safe and Effective Loading Dose Regimen

BACKGROUND: Contezolid (CZD) is a novel oral oxazolidnone with comparable activity and potentially improved safety compared to current oxazolidinones. The intravenous (IV) double prodrug contezolid acefosamil (CZDa) is converted via MRX-1352 to active CZD. CZDa paired with CZD holds promise as a saf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bulitta, Jürgen B, Hafkin, Barry, Fang, Edward
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644342/ http://dx.doi.org/10.1093/ofid/ofab466.1311

Ejemplares similares

1700. Efficacy and Safety in Subjects with Renal Impairment in Contezolid and Contezolid Acefosamil Phase 2 and Phase 3 Skin Infection Clinical Trials
por: Fang, Edward, et al.
Publicado: (2022)

A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects
por: Yang, Haijing, et al.
Publicado: (2023)

Contezolid: First Approval
por: Hoy, Sheridan M.
Publicado: (2021)

Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis
por: Wu, Junzhen, et al.
Publicado: (2023)

1701. Pharmacokinetics in Subjects with Renal Impairment in a Contezolid Complicated Skin and Soft Tissue Infection Phase 3 Clinical Trial
por: Fang, Edward, et al.
Publicado: (2022)

Clinical Utility of Contezolid-Containing Regimens in 25 Cases of Linezolid-Intolerable Tuberculosis Patients
por: Wang, Jun, et al.
Publicado: (2023)

2710. Long Term Use of Contezolid in Lung Transplant Recipients Infected with Nocardia Species
por: Ju, Chunrong
Publicado: (2023)

662. In vitro antibacterial activity of contezolid compared to linezolid and vancomycin in clinical isolates from China
por: Wang, Shanmei, et al.
Publicado: (2022)

1702. Platelet Counts in Contezolid Complicated Skin and Soft Tissue Infection Phase 2 and Phase 3 Clinical Trials
por: Fang, Edward, et al.
Publicado: (2022)

Antibacterial activity of the novel oxazolidinone contezolid (MRX-I) against Mycobacterium abscessus
por: Gao, Shan., et al.
Publicado: (2023)

Compassionate Use of Contezolid for the Treatment of Tuberculous Pleurisy in a Patient with a Leadless Pacemaker
por: Kang, Yixin, et al.
Publicado: (2022)

A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro
por: Guo, Qi, et al.
Publicado: (2021)

In vitro activities of contezolid (MRX-I) against drug-sensitive and drug-resistant Mycobacterium tuberculosis
por: An, Huiru, et al.
Publicado: (2023)

Case report: Successful treatment with contezolid in a patient with tuberculous meningitis who was intolerant to linezolid
por: Xu, Zhe, et al.
Publicado: (2023)

Development and Validation of an LC-MS/MS Method for the Quantitative Determination of Contezolid in Human Plasma and Cerebrospinal Fluid
por: Zhang, Guanxuanzi, et al.
Publicado: (2022)

Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment
por: Li, Bi, et al.
Publicado: (2023)

Use of Contezolid for the Treatment of Refractory Infective Endocarditis in a Patient with Chronic Renal Failure: Case Report
por: Zhao, Sheng, et al.
Publicado: (2023)

Sequential Therapy of Linezolid and Contezolid to Treat Vancomycin-Resistant Enterococcus faecium Pneumonia in a Centenarian Patient: Case Report
por: Chen, Pengzhi, et al.
Publicado: (2023)

Sequential Therapy of Linezolid and Contezolid to Treat Vancomycin-Resistant Enterococcus faecium Pneumonia in a Centenarian Patient: Case Report [Corrigendum]
Publicado: (2023)

697. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06)
por: Yang, Yang, et al.
Publicado: (2019)

686. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06)
por: Yang, Yang, et al.
Publicado: (2019)

In vitro Activity of Contezolid Against Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus, and Strains With Linezolid Resistance Genes From China
por: Wang, Siheng, et al.
Publicado: (2021)

Severe Community-Acquired Pneumonia Caused by Methicillin-Sensitive Staphylococcus aureus: Successfully Treated with Contezolid – A Case Report and Literature Review
por: Wang, Kaifei, et al.
Publicado: (2023)

Rare tuberculosis in recipients of allogeneic hematopoietic stem cell transplantation successfully treated with contezolid–a typical case report and literature review
por: Li, Junhong, et al.
Publicado: (2023)

1118. Trends of Paediatric Prescribing for Common Infections in British Columbia
por: Saatchi, Ariana, et al.
Publicado: (2019)

1118. Development of a Curriculum for Internal Medicine Residents on Latent and Active Pulmonary TB: A Targeted Needs Assessment
por: Sherwood, Kyla, et al.
Publicado: (2020)

1118. Viral Species Richness and Composition in Young Children With Loose or Watery Stool in Ethiopia
por: Aiemjoy, Kristen, et al.
Publicado: (2018)

Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications
por: Trujillo, Toby, et al.
Publicado: (2014)

Erratum to: Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications
por: Trujillo, Toby, et al.
Publicado: (2014)

P-022: THERAPEUTIC EFFECTS OF GBT1118 ON SKELETAL MUSCLE ENERGETICS AND FUNCTION IN SICKLE CELL MICE
por: C., MICHEL, et al.
Publicado: (2022)

P1118: PROGNOSTIC SIGNIFICANCE OF ABSOLUTE MONOCYTE COUNT AND LYMPHOCYTE TO MONOCYTE RATIO IN MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA
por: Li, Y., et al.
Publicado: (2022)

971. Pharmacokinetic Estimation Analysis of Multi-Dose Regimens of Dalbavancin for Treatment of Osteomyelitis or Bacteremia
por: Volk, Cecilia, et al.
Publicado: (2023)

739. Prediction of Cefiderocol Pharmacokinetics and Probability of Target Attainment in Pediatric Subjects for Proposing Dose Regimens
por: Katsube, Takayuki, et al.
Publicado: (2019)

1084. Comparative Outcomes Among Patients Receiving Varying Daptomycin Dosing Regimens in Hemodialysis
por: Maxwell, Tyler, et al.
Publicado: (2021)

1563. Population Pharmacokinetics and Pharmacodynamics of Daily and Extended Interval Dalbavancin Dosing Regimens for Salvage Therapy of Staphylococcus aureus Endocarditis: Mechanistic Modeling of Rabbit Infection Data to Support Human Dosing Regimens
por: Farkas, Andras, et al.
Publicado: (2019)

734. Modeling the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Omadacycline with and without a Loading Dose
por: Friedrich, Lawrence, et al.
Publicado: (2019)

576. Half-dose Valganciclovir Prophylaxis is Safe and Cost-effective in CMV Seropositive Renal Transplant Recipients
por: shi, yiyun, et al.
Publicado: (2020)

Drosophila melanogaster White Mutant w(1118) Undergo Retinal Degeneration
por: Ferreiro, María José, et al.
Publicado: (2018)

Rheological Impact of GBT1118 Cessation in a Sickle Mouse Model
por: Kanne, Celeste K., et al.
Publicado: (2021)

Improvement of hemolytic anemia with GBT1118 is renoprotective in transgenic sickle mice
por: Ren, Guohui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_udcmc126npl9t810tevtah334l